GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Median PS Value
中文

Northwest Biotherapeutics (Northwest Biotherapeutics) Median PS Value : $0.00 (As of Apr. 24, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Northwest Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.001. Northwest Biotherapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-24), Northwest Biotherapeutics's share price is $0.4601. Northwest Biotherapeutics's Median PS Value is $0.00. Therefore, Northwest Biotherapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Northwest Biotherapeutics's Median PS Value or its related term are showing as below:

During the past 13 years, the highest Price to Median PS Value of Northwest Biotherapeutics was 4.62. The lowest was 0.08. And the median was 0.32.

NWBO's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Northwest Biotherapeutics Median PS Value Historical Data

The historical data trend for Northwest Biotherapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Median PS Value Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 0.33 - - -

Northwest Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Northwest Biotherapeutics's Median PS Value

For the Biotechnology subindustry, Northwest Biotherapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Price-to-Median-PS-Value falls into.



Northwest Biotherapeutics Median PS Value Calculation

Northwest Biotherapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.001*0
=0.00

10-Year Median PS Ratio is 0.
Northwest Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Northwest Biotherapeutics  (OTCPK:NWBO) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Northwest Biotherapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.4601/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Northwest Biotherapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics (Northwest Biotherapeutics) Headlines

From GuruFocus